AgomAb Therapeutics: Funding, Investors & Team (Sep 2026)
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic monoclonal immunizer particles ("agomAbs") animate atomic and cell fix systems that can possibly reestablish organ capability in patients with fibrotic, fiery, immune system and degenerative illnesses.
AgomAb Therapeutics has raised $228M across 3 funding rounds on record, the most recent a Series D of $88.8M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
AgomAb Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2024.
AgomAb Therapeutics Funding Rounds
AgomAb Therapeutics raised $38.5M in a Series B announced in Jul 2022.
1.3 years later, a Series C of $101M was announced in Oct 2023.
1 years later, a Series D of $88.8M was announced in Oct 2024.
AgomAb Therapeutics Founders and Leadership Team
Contact details for the AgomAb Therapeutics team: 2 of 3 have an email address on file.
Start 14-day free trial →AgomAb Therapeutics Funding Compared to Other Biotechnology Startups
AgomAb Therapeutics' latest round of $88.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like AgomAb Therapeutics in Biotechnology and Ghent
Companies Similar to AgomAb Therapeutics
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global…
AgomAb Therapeutics Funding FAQs
What does AgomAb Therapeutics do?
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic monoclonal immunizer particles ("agomAbs") animate atomic and cell fix systems that can possibly reestablish organ capability in patients with fibrotic, fiery, immune system and degenerative illnesses.
How much funding has AgomAb Therapeutics raised?
AgomAb Therapeutics has raised $228M across 3 rounds on record. The most recent is a Series D of $88.8M announced in Oct 2024.
When did AgomAb Therapeutics last raise funding?
AgomAb Therapeutics' most recent funding round on record is a Series D of $88.8M, announced in Oct 2024.
Who founded AgomAb Therapeutics?
FundedIQ lists Federica Linty (Founder), Manuela Cazzanti (Founder), Virginia Morello (Founder) at AgomAb Therapeutics.
Where is AgomAb Therapeutics headquartered?
AgomAb Therapeutics is based in Ghent, Oost-Vlaanderen, Belgium.
How many employees does AgomAb Therapeutics have?
AgomAb Therapeutics is in the 1-10 employee band.
How does AgomAb Therapeutics' funding compare to other Biotechnology startups?
AgomAb Therapeutics' latest round of $88.8M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's AgomAb Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for AgomAb Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.